| Eli Lilly & Co. | Targeted Therapy & Precision Oncology | $1.3t | $1369.78 | -0.9% | 9.2K | |
| Johnson & Johnson | Immunotherapy & Immuno-Oncology | $0.6t | $270.59 | -0.8% | 10.5K | |
| ABBVIE INC. | Immunotherapy & Immuno-Oncology | $0.5t | $283.06 | -1.1% | 8.3K | |
| Merck & Co., Inc. | Immunotherapy & Immuno-Oncology | $356.9b | $136.55 | -0.8% | 5.3K | |
| AstraZeneca PLC | Immunotherapy & Immuno-Oncology | $285.2b | $176.68 | -1.0% | 7.1K | |
| Amgen Inc | Immunotherapy & Immuno-Oncology | $249.4b | $445.05 | 0.0% | 7.1K | |
| Gilead Sciences Inc | Cell & Gene Therapy for Cancer | $207.7b | $167.58 | 0.0% | 8.5K | |
| Bristol-Myers Squibb Co. | Immunotherapy & Immuno-Oncology | $126.1b | $59.06 | -0.4% | 8.8K | |
| Regeneron Pharmaceuticals Inc | Immunotherapy & Immuno-Oncology | $100.7b | $950.07 | 0.0% | 255 | |
| Moderna, Inc. Common Stock | Immunotherapy & Immuno-Oncology | $91.2b | $198.36 | 0.0% | 62.6K | |
| Natera, Inc. Common Stock | Cancer Diagnostics & Biomarkers | $56.0b | $293.05 | 0.0% | 2.8K | |
| Revolution Medicines, Inc. Common Stock | Targeted Therapy & Precision Oncology | $41.6b | $160.93 | 0.0% | 230 | |
| Royalty Pharma plc Class A Ordinary Shares | Immunotherapy & Immuno-Oncology | $29.6b | $68.93 | 0.0% | 146 | |
| Incyte Genomics Inc | Targeted Therapy & Precision Oncology | $24.0b | $117.74 | 0.0% | 10 | |
| Guardant Health, Inc. Common Stock | Cancer Diagnostics & Biomarkers | $23.5b | $146.75 | 0.0% | 296 | |
| Exelixis Inc | Targeted Therapy & Precision Oncology | $17.6b | $68.84 | 0.0% | 12.3K | |
| Jazz Pharmaceuticals, Inc. | Targeted Therapy & Precision Oncology | $14.9b | $248.24 | 0.0% | 948 | |
| Halozyme Therapeutics, Inc. | Targeted Therapy & Precision Oncology | $14.6b | $96.47 | 0.0% | 71 | |
| Nuvalent, Inc. Class A Common Stock | Targeted Therapy & Precision Oncology | $9.8b | $123.96 | 0.0% | N/A | |
| Caris Life Sciences, Inc. Common Stock | Cancer Diagnostics & Biomarkers | $9.3b | $19.80 | 0.0% | 10.6K | |
| Corcept Therapeutics Inc. | Targeted Therapy & Precision Oncology | $8.9b | $68.50 | 0.0% | 437 | |
| ImmunityBio, Inc. Common Stock | Immunotherapy & Immuno-Oncology | $8.8b | $6.79 | 0.0% | 62.9K | |
| Arcellx, Inc. Common Stock | Cell & Gene Therapy for CancerImmunotherapy & Immuno-Oncology | $6.7b | $115.06 | -0.0% | 16.1M | |
| Lantheus Holdings, Inc | Radiopharmaceuticals & ADCs | $6.6b | $102.14 | 0.0% | 66 | |
| GRAIL, Inc. Common Stock | Cancer Diagnostics & Biomarkers | $6.2b | $106.30 | 0.0% | 1.2K | |
| CG Oncology, Inc. Common stock | Immunotherapy & Immuno-Oncology | $5.7b | $84.72 | 0.0% | 526 | |
| Cogent Biosciences, Inc. Common Stock | Targeted Therapy & Precision Oncology | $5.4b | $28.10 | 0.0% | 3.2K | |
| BillionToOne, Inc. Class A Common Stock | Cancer Diagnostics & Biomarkers | $5.2b | $91.67 | 0.0% | 238 | |
| Erasca, Inc. Common Stock | Targeted Therapy & Precision Oncology | $5.1b | $13.80 | 0.0% | 906 | |
| Adaptive Biotechnologies Corporation Common Stock | Cancer Diagnostics & Biomarkers | $4.1b | $28.55 | 0.0% | 526 | |
| Veracyte, Inc. | Cancer Diagnostics & Biomarkers | $4.0b | $25.95 | 0.0% | 3.4K | |
| Iovance Biotherapeutics, Inc. Common Stock | Cell & Gene Therapy for CancerImmunotherapy & Immuno-Oncology | $4.0b | $7.59 | 0.0% | 29.0K | |
| AbCellera Biologics Inc. Common Shares | Radiopharmaceuticals & ADCs | $3.9b | $11.32 | 0.0% | 4.3K | |
| Tango Therapeutics, Inc. | Targeted Therapy & Precision Oncology | $3.9b | $22.05 | 0.0% | 313 | |
| Relay Therapeutics, Inc. Common Stock | Targeted Therapy & Precision Oncology | $3.8b | $16.50 | 0.0% | 523 | |
| Parabilis Medicines, Inc. Common Stock | Targeted Therapy & Precision Oncology | $3.6b | $28.64 | 0.0% | 1.7K | |
| Celcuity Inc. Common Stock | Targeted Therapy & Precision Oncology | $3.4b | $56.01 | 0.0% | 11.5K | |
| Enliven Therapeutics, Inc. Common Stock | Targeted Therapy & Precision Oncology | $3.2b | $45.53 | 0.0% | 3 | |
| IDEAYA Biosciences, Inc. Common Stock | Targeted Therapy & Precision Oncology | $3.0b | $26.85 | 0.0% | 8 | |
| Nurix Therapeutics, Inc. Common stock | Targeted Therapy & Precision Oncology | $2.8b | $13.75 | 0.0% | 547 | |
| Arcus Biosciences, Inc. | Immunotherapy & Immuno-Oncology | $2.4b | $16.18 | +1.0% | 4.4K | |
| Immunome, Inc. | Targeted Therapy & Precision OncologyRadiopharmaceuticals & ADCs | $2.4b | $16.89 | 0.0% | 1.5K | |
| Biohaven Ltd. | Targeted Therapy & Precision Oncology | $2.4b | $13.08 | -0.1% | 24.6K | |
| Xencor, Inc. | Immunotherapy & Immuno-Oncology | $2.3b | $34.47 | 0.0% | 332 | |
| Day One Biopharmaceuticals, Inc. Common Stock | Targeted Therapy & Precision Oncology | $2.2b | $21.52 | -0.0% | 3.0M | |
| NeoGenomics, Inc. | Cancer Diagnostics & Biomarkers | $2.2b | $15.52 | 0.0% | 1.2K | |
| Zymeworks Inc. | Targeted Therapy & Precision Oncology | $2.2b | $26.04 | 0.0% | 579 | |
| Replimune Group, Inc. | Immunotherapy & Immuno-Oncology | $2.0b | $19.75 | 0.0% | 247 | |
| Vir Biotechnology, Inc. Common Stock | Targeted Therapy & Precision Oncology | $1.9b | $9.20 | 0.0% | 77 | |
| Precigen, Inc. Common Stock | Immunotherapy & Immuno-Oncology | $1.9b | $4.35 | 0.0% | 1.2K |